Curexo Inc. (060280.KQ)
KRW 6560.0
(-4.51%)
KRW 6560.0
(-4.51%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 17.95 Billion KRW | 34.07% |
| 2022 | 13.39 Billion KRW | 60.78% |
| 2021 | 8.33 Billion KRW | -4.44% |
| 2020 | 8.71 Billion KRW | 78.14% |
| 2019 | 4.89 Billion KRW | -12.94% |
| 2018 | 5.62 Billion KRW | 1.11% |
| 2017 | 5.55 Billion KRW | 283.76% |
| 2016 | 1.44 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 3.32 Billion KRW | -28.61% |
| 2024 Q2 | 2.76 Billion KRW | -1.73% |
| 2023 Q1 | 4.92 Billion KRW | 15.51% |
| 2023 Q2 | 4.39 Billion KRW | -10.76% |
| 2023 Q3 | 3.97 Billion KRW | -9.55% |
| 2023 Q4 | 4.65 Billion KRW | 17.21% |
| 2023 FY | 17.95 Billion KRW | 34.07% |
| 2022 Q2 | 2.31 Billion KRW | -17.65% |
| 2022 FY | 13.39 Billion KRW | 60.78% |
| 2022 Q4 | 4.26 Billion KRW | 8.15% |
| 2022 Q3 | 3.94 Billion KRW | 70.01% |
| 2022 Q1 | 2.81 Billion KRW | -13.47% |
| 2021 FY | 8.33 Billion KRW | -4.44% |
| 2021 Q4 | 3.25 Billion KRW | 93.37% |
| 2021 Q3 | 1.68 Billion KRW | 0.0% |
| 2020 FY | 8.71 Billion KRW | 78.14% |
| 2019 FY | 4.89 Billion KRW | -12.94% |
| 2018 FY | 5.62 Billion KRW | 1.11% |
| 2017 FY | 5.55 Billion KRW | 283.76% |
| 2016 FY | 1.44 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 219.75 Billion KRW | 91.829% |
| InBody Co.,Ltd | 128.11 Billion KRW | 85.984% |
| Seegene, Inc. | 180.07 Billion KRW | 90.028% |
| i-SENS, Inc. | 101.04 Billion KRW | 82.229% |
| Ray Co., Ltd. | 65.08 Billion KRW | 72.412% |
| Gencurix Inc. | 422.03 Million KRW | -4154.713% |
| Sugentech Inc. | -5.88 Billion KRW | 405.334% |
| L&C Bio Co., Ltd | 32.52 Billion KRW | 44.796% |